- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00749957
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2
The purpose of the study is to evaluate the safety and efficacy of an adeno-associated virus vector expressing RPE65 in patients with Leber congenital amaurosis caused by mutations in the RPE65 gene.
Funding Source - FDA OOPD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a non-randomized, open label study. A total of 12 participants will be enrolled into two groups of 6 each. Each participant will receive rAAV2 CB hRPE65 by subretinal injection in one eye on a single occasion. Participants in Group 1 will receive 450 µL at a dosage level of 4 x 10^11 vg/mL containing a total of 1.8 x 10^11 vg of rAAV2-CB-hRPE65. Participants in Group 2 will receive 450 µL at a dosage level of 1.33 x 10^12 vg/mL containing a total of 6 x 10^11 vg of rAAV2-CB-hRPE65. A retinal surgeon will administer the vector by subretinal injection.
Enrollment will begin with Group 1 and will proceed to Group 2 after review of safety data by a Data and Safety Monitoring Committee.
Safety will be monitored by evaluation of ocular and non ocular adverse events and hematology and clinical chemistry parameters. Efficacy will be measured by evaluation of visual fields, visual acuity and electroretinography.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- University of Massachusetts Medical School
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Casey Eye Institue, Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Retinal disease consistent with a diagnosis of Leber congenital amaurosis and documented mutations in the RPE65 gene (including null mutations and mutations that code for abnormal RPE65 protein);
- At least 6 years of age;
- Good general health without significant physical examination findings or clinically significant abnormal laboratory results;
- Able to perform tests of visual and retinal function;
- Visual acuity not better than 20/60 and not worse than hand motion in both the treated eye and the fellow eye;
- Visible photoreceptor (outer nuclear) layer on a standard optical coherence tomography (OCT) scan;
- Acceptable hematology, clinical chemistry and urine laboratory parameters;
- For females of childbearing potential, a negative pregnancy test at screening and at baseline, and agreement to use effective contraception for 12 months after administration of rAAV2-CB-hRPE65, for sexual activity that could lead to pregnancy;
- For males of reproductive potential, agreement to use effective contraception for 12 months after administration of rAAV2-CB-hRPE65, for sexual activity that could lead to pregnancy
Exclusion Criteria:
- Pre-existing eye conditions that would preclude the planned surgery or interfere with interpretation of study endpoints or complications of surgery (e.g. glaucoma, corneal or lenticular opacities, or history or retinal detachment);
- Presence of epiretinal membrane on OCT;
- History of immunodeficiency or other medical conditions that might increase the risk of rAAV2-CB-hRPE65 administration;
- Use of anticoagulants or anti-platelet agents within 7 days prior to study agent administration;
- History of allergy or sensitivity to medications planned for use in the peri-operative period;
- For females of childbearing potential, a positive pregnancy test at screening or baseline (within 2 days before rAAV2-CB-hRPE65 administration);
- Females who are breast feeding;
- Use of any investigational agent, or systemic corticosteroids or other immunosuppressive drug(s), within 3 months prior to enrollment;
- Prior receipt of any AAV gene therapy product;
- Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Subjects at least 6 y/o treated with a lower dose of the vector by subretinal injection
|
Recombinant adeno-associated virus vector expressing RPE65
|
Experimental: 2
Subjects at least 6 y/o treated with a higher dose of the vector by subretinal injection
|
Recombinant adeno-associated virus vector expressing RPE65
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Experiencing Ocular or Non-ocular Adverse Events
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants With Changes in Visual Fields
Time Frame: 2 years
|
Improvement in the central 30 degree visual field, measured by static perimetry, at one or more time points after treatment, that was greater than the limit of agreement for baseline values .
|
2 years
|
Participants With Changes in Best Corrected Visual Acuity
Time Frame: 2 years
|
Increase in BCVA of 7 or more letters at Year 2 visit compared to average baseline value
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: J Timothy Stout, MD, PhD, MBA, Casey Eye Institute, Oregon Health & Science University
Publications and helpful links
General Publications
- Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J, Dejneka NS, Pearce-Kelling SE, Maguire AM, Palczewski K, Hauswirth WW, Jacobson SG. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther. 2005 Dec;12(6):1072-82. doi: 10.1016/j.ymthe.2005.08.008. Epub 2005 Oct 14.
- Jacobson SG, Boye SL, Aleman TS, Conlon TJ, Zeiss CJ, Roman AJ, Cideciyan AV, Schwartz SB, Komaromy AM, Doobrajh M, Cheung AY, Sumaroka A, Pearce-Kelling SE, Aguirre GD, Kaushal S, Maguire AM, Flotte TR, Hauswirth WW. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther. 2006 Aug;17(8):845-58. doi: 10.1089/hum.2006.17.845.
- Weleber RG, Pennesi ME, Wilson DJ, Kaushal S, Erker LR, Jensen L, McBride MT, Flotte TR, Humphries M, Calcedo R, Hauswirth WW, Chulay JD, Stout JT. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. Ophthalmology. 2016 Jul;123(7):1606-20. doi: 10.1016/j.ophtha.2016.03.003. Epub 2016 Apr 19.
- Pennesi ME, Weleber RG, Yang P, Whitebirch C, Thean B, Flotte TR, Humphries M, Chegarnov E, Beasley KN, Stout JT, Chulay JD. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy. Hum Gene Ther. 2018 Dec;29(12):1428-1437. doi: 10.1089/hum.2018.014. Epub 2018 Jul 24.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AGTC-RPE65-002
- R01FD003694 (U.S. FDA Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leber Congenital Amaurosis
-
ProQR TherapeuticsActive, not recruitingEye Diseases | Neurologic Manifestations | Eye Diseases, Hereditary | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders CongenitalUnited States, Belgium, Brazil, Canada, France, Germany, Italy, Netherlands, United Kingdom
-
University of PennsylvaniaNational Eye Institute (NEI)Active, not recruitingRetinal Diseases | Amaurosis of LeberUnited States
-
ProQR TherapeuticsTerminatedEye Diseases | Neurologic Manifestations | Eye Diseases, Hereditary | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders CongenitalUnited States, Belgium
-
QLT Inc.CompletedLCA (Leber Congenital Amaurosis) | RP (Retinitis Pigmentosa)United States, Canada, Germany, Netherlands, United Kingdom
-
ProQR TherapeuticsRecruitingEye Diseases | Neurologic Manifestations | Retinal Degeneration | Retinal Dystrophies | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders CongenitalBelgium, Brazil, Canada, Germany, Italy, Netherlands, United Kingdom
-
Eyecure Therapeutics Inc.Beijing Tongren HospitalUnknownLeber Congenital Amaurosis, Retinitis PigmentosaChina
-
QLT Inc.CompletedLCA (Leber Congenital Amaurosis) | RP (Retinitis Pigmentosa)Canada, United States, Germany, Netherlands, United Kingdom
-
ProQR TherapeuticsCompletedLeber's Congenital AmaurosisUnited States, Belgium
-
University of Campania "Luigi Vanvitelli"Retina Italia OnlusCompletedLeber Congenital Amaurosis 2 | Retinitis Pigmentosa 20Italy
-
QLT Inc.CompletedLeber Congenital Amaurosis (LCA) | Retinitis Pigmentosa (RP)United States, Canada, Denmark, Germany, Netherlands, Switzerland, United Kingdom
Clinical Trials on rAAV2-CB-hRPE65
-
University of PennsylvaniaNational Eye Institute (NEI)Active, not recruitingRetinal Diseases | Amaurosis of LeberUnited States
-
Nantes University HospitalCompletedLeber Congenital AmaurosisFrance
-
Hadassah Medical OrganizationCompletedLeber Congenital AmaurosisIsrael
-
University of Massachusetts, WorcesterNational Heart, Lung, and Blood Institute (NHLBI); University of Florida; National... and other collaboratorsCompletedAlpha 1-Antitrypsin DeficiencyUnited States
-
Bin LiUnknownAcute LHON | Onset Within Three Months | Onset Between 3 to 6 Months | Onset Between 6 to 12 Months | Onset Between 12 to 24 Months | Onset Between 24 to 60 Months | Onset Over 60 MonthsChina
-
Huazhong University of Science and TechnologyShiyan Taihe HospitalActive, not recruitingLeber Hereditary Optic NeuropathyChina
-
University of AlbertaCanadian Institutes of Health Research (CIHR); Imperial College London; University... and other collaboratorsCompleted
-
STZ eyetrialUniversity Hospital TuebingenCompleted
-
Digna Biotech S.L.University of Navarra; Porphyria Centre Sweden; UniQure N.V.; Nationales Centrum...CompletedAcute Intermittent PorphyriaSpain
-
Bin LiHuazhong University of Science and TechnologyCompletedLeber Hereditary Optic NeuropathyChina